Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 11/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.37 |
| ▸ | PPARA | Q07869 | 5/20 | 0.36 |
| ▸ | PPARD | Q03181 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533914 | 1.00 | PTGDR2 (0.59) | PTGDR2TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL534119 | 0.91 | PTGDR2 (0.55) | PTGDR2P2RX3 | |
| SCHEMBL534118 | 0.91 | PTGDR2 (0.55) | PTGDR2P2RX3 | |
| SCHEMBL3770942 | 0.88 | PTGDR2 (0.74) | PTGDR2TSHRPPARGP2RX3PPARA | |
| SCHEMBL3778499 | 0.88 | PTGDR2 (0.48) | PTGDR2TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL3778507 | 0.88 | PTGDR2 (0.48) | PTGDR2TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL3782624 | 0.85 | PTGDR2 (0.63) | PTGDR2TSHRP2RX3 | |
| SCHEMBL3776129 | 0.81 | PTGDR2 (0.78) | PTGDR2PPARD | |
| SCHEMBL3779879 | 0.81 | PTGDR2 (0.64) | PTGDR2TSHRP2RX3PPARD | |
| SCHEMBL534256 | 0.80 | PTGDR2 (0.73) | PTGDR2TSHRPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2129661-B1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-02-08 | — | — | EP | claimed |
| US-20100144786-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-06-10 | — | — | US | claimed |
| EP-2129661-B1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-02-08 | — | — | EP | disclosed |
| US-20100144786-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| EP-2129661-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | Argenta Oral Therapeutics Limited (GB) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008119917-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | ARGENTA DISCOVERY LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144786-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | NR1H2, GPR52, HRH2 | PTGDR2 75/4885TSHR 447/4885HTR2A 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.